Markers of instability in high-risk carotid plaques are reduced by statins

Journal of Vascular Surgery

Volumn 47, Issue 3, 2008, Pages 513-522

  Kunte, Hagen ^a   Amberger, Nicola ^a   Busch, Markus Alexander ^a   Rückert, Ralph Ingo ^b   Meiners, Silke ^a   Harms, Lutz ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MARTIN LUTHER KRANKENHAUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CAROTID ENDARTERECTOMY; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE MARKER; DRUG MECHANISM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERNAL CAROTID ARTERY OCCLUSION; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

AGED; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL MARKERS; CAROTID ARTERY, INTERNAL; CAROTID STENOSIS; CEREBROVASCULAR DISORDERS; ENDARTERECTOMY, CAROTID; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOHISTOCHEMISTRY; INFLAMMATION MEDIATORS; MACROPHAGES; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; ODDS RATIO; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RUPTURE; TIME FACTORS;

EID: 39149090382     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2007.11.045     Document Type: Article

References (37)

1. Sacco R.L., Ellenberg J.H., Mohr J.P., Tatemichi T.K., Hier D.B., Price T.R., et al. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol 25 (1989) 382-390
2. Golledge J., Greenhalgh R.M., and Davies A.H. The symptomatic carotid plaque. Stroke 31 (2000) 774-781
3. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
4. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
5. Bassiouny H.S., Sakaguchi Y., Mikucki S.A., McKinsey J.F., Piano G., Gewertz B.L., et al. Juxtalumenal location of plaque necrosis and neoformation in symptomatic carotid stenosis. J Vasc Surg 26 (1997) 585-594
6. Carr S.C., Farb A., Pearce W.H., Virmani R., and Yao J.S. Activated inflammatory cells are associated with plaque rupture in carotid artery stenosis. Surgery 122 (1997) 757-763
7. Jander S., Sitzer M., Schumann R., Schroeter M., Siebler M., Steinmetz H., et al. Inflammation in high-grade carotid stenosis: a possible role for macrophages and T cells in plaque destabilization. Stroke 29 (1998) 1625-1630
8. Lehtonen-Smeds E.M., Mayranpaa M., Lindsberg P.J., Soinne L., Saimanen E., Jarvinen A.A., et al. Carotid plaque mast cells associate with atherogenic serum lipids, high grade carotid stenosis and symptomatic carotid artery disease. Results from the Helsinki carotid endarterectomy study. Cerebrovasc Dis 19 (2005) 291-301
9. Fatar M., Stroick M., Griebe M., and Hennerici M. Matrix metalloproteinases in cerebrovascular diseases. Cerebrovasc Dis 20 (2005) 141-151
10. Higashikata T., Yamagishi M., Higashi T., Nagata I., Iihara K., Miyamoto S., et al. Altered expression balance of matrix metalloproteinases and their inhibitors in human carotid plaque disruption: Results of quantitative tissue analysis using real-time RT-PCR method. Atherosclerosis 185 (2006) 165-172
11. Plehn J.F., Davis B.R., Sacks F.M., Rouleau J.L., Pfeffer M.A., Bernstein V., et al. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation 99 (1999) 216-223
12. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339 (1998) 1349-1357
13. Waters D.D., Schwartz G.G., Olsson A.G., Zeiher A., Oliver M.F., Ganz P., et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 106 (2002) 1690-1695
14. Collins R., Armitage J., Parish S., Sleight P., and Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363 (2004) 757-767
15. Amarenco P., Bogousslavsky J., Callahan III A., Goldstein L.B., Hennerici M., Rudolph A.E., et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 (2006) 549-559
16. Endres M. Statins and stroke. J Cereb Blood Flow Metab 25 (2005) 1093-1110
17. Kwak B.R., Mulhaupt F., and Mach F. Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmun Rev 2 (2003) 332-338
18. Takemoto M., and Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21 (2001) 1712-1719
19. Aikawa M., Rabkin E., Sugiyama S., Voglic S.J., Fukumoto Y., Furukawa Y., et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 103 (2001) 276-283
20. Bellosta S., Via D., Canavesi M., Pfister P., Fumagalli R., Paoletti R., et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 18 (1998) 1671-1678
21. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., and Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103 (2001) 926-933
22. Verhoeven B.A., Moll F.L., Koekkoek J.A., van der Wal A.C., de Kleijn D.P., de Vries J.P., et al. Statin treatment is not associated with consistent alterations in inflammatory status of carotid atherosclerotic plaques: a retrospective study in 378 patients undergoing carotid endarterectomy. Stroke 37 (2006) 2054-2060
23. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 325 (1991) 445-453
24. Redgrave J.N., Lovett J.K., Gallagher P.J., and Rothwell P.M. Histological assessment of 526 symptomatic carotid plaques in relation to the nature and timing of ischemic symptoms: the Oxford plaque study. Circulation 113 (2006) 2320-2328
25. Loftus I.M., Naylor A.R., Goodall S., Crowther M., Jones L., Bell P.R., et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke 31 (2000) 40-47
26. Aikawa M., Rabkin E., Sugiyama S., Voglic S.J., Fukumoto Y., Furukawa Y., et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 103 (2001) 276-283
27. Serrano Jr. C.V., Yoshida V.M., Venturinelli M.L., D'Amico E., Monteiro H.P., Ramires J.A., et al. Effect of simvastatin on monocyte adhesion molecule expression in patients with hypercholesterolemia. Atherosclerosis 157 (2001) 505-512
28. Bustos C., Hernandez-Presa M.A., Ortego M., Tunon J., Ortega L., Perez F., et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 32 (1998) 2057-2064
29. Senokuchi T., Matsumura T., Sakai M., Yano M., Taguchi T., Matsuo T., et al. Statins suppress oxidized low density lipoprotein-induced macrophage proliferation by inactivation of the small G protein-p38 MAPK pathway. J Biol Chem 280 (2005) 6627-6633
30. Jander S., Sitzer M., Wendt A., Schroeter M., Buchkremer M., Siebler M., et al. Expression of tissue factor in high-grade carotid artery stenosis: association with plaque destabilization. Stroke 32 (2001) 850-854
31. Golledge J., Greenhalgh R.M., and Davies A.H. The symptomatic carotid plaque. Stroke 31 (2000) 774-781
32. Li C., Mollahan P., Baguneid M.S., McMahon R.F., Kumar P., Walker M.G., et al. A comparative study of neovascularisation in atherosclerotic plaques using CD31, CD105 and TGF beta 1. Pathobiology 73 (2006) 192-197
33. Kawahara I., Kitagawa N., Tsutsumi K., Nagata I., Hayashi T., and Koji T. The expression of vascular dendritic cells in human atherosclerotic carotid plaques. Hum Pathol 38 (2007) 1378-1385
34. Rothwell P.M., Eliasziw M., Gutnikov S.A., Warlow C.P., and Barnett H.J. Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 363 (2004) 915-924
35. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
36. Amarenco P., Labreuche J., Lavallee P., and Touboul P.J. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 35 (2004) 2902-2909
37. Paciaroni M., Hennerici M., Agnelli G., and Bogousslavsky J. Statins and stroke prevention. Cerebrovasc Dis 24 (2007) 170-182